ClinConnect ClinConnect Logo
Search / Trial NCT06121102

Standard Pulsed Radiofrequency Versus Supervoltage Pulsed Radiofrequency Glossopharyngeal Nerve in Oropharyngeal Cancer Pain

Launched by NATIONAL CANCER INSTITUTE, EGYPT · Nov 5, 2023

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for managing pain in patients with oropharyngeal cancer, which affects the throat area. The researchers want to compare the effectiveness and safety of a newer treatment called supervoltage pulsed radiofrequency against a standard treatment called pulsed radiofrequency. Both methods aim to reduce pain, which is measured using a scale where patients rate their discomfort.

To participate in this study, you need to be between 18 and 70 years old and have been experiencing significant pain (rated 6 or higher on a scale of 0 to 10) despite other treatments. The trial is seeking both men and women who have not found relief from their pain through medication. However, some individuals may not be eligible, such as those with certain medical conditions, severe allergies to the treatment, or who are unable to lie flat during the procedure. If you join the trial, you will receive either of the two treatments and be monitored for how well it helps with your pain. The study is currently recruiting participants, so there is an opportunity to take part in this important research.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 and ≤ 70 Years.
  • Both sexes
  • American Society of Anesthesiologists (ASA) class II and III.
  • Patients under pain management for oropharyngeal cancer (failed medical treatment or intolerance to the side effects of the drug).
  • Visual analog scale (VAS) equal to or more than 6 cm in spite medical treatment.
  • Exclusion Criteria:
  • Patient refusal.
  • Patients with local or systemic sepsis.
  • Uncorrectable coagulopathy.
  • Unstable cardiovascular disease.
  • History of psychiatric and cognitive disorders.
  • Patients allergic to medication used.7
  • Unable to lie supine.
  • Local anatomical distortion (either congenital, post-surgical or post-radiotherapy) making intervention difficult and hazardous.
  • Elongated styloid process \> 25 mm.
  • Age less than 18 year and more than 70 year.

About National Cancer Institute, Egypt

The National Cancer Institute, Egypt, is a premier research institution dedicated to advancing cancer prevention, treatment, and care through innovative clinical trials and comprehensive research initiatives. As a leading sponsor of clinical studies, the Institute focuses on understanding cancer biology, improving therapeutic strategies, and enhancing patient outcomes. With a commitment to scientific excellence and collaboration, the National Cancer Institute plays a crucial role in addressing the cancer burden in Egypt and the broader region, fostering partnerships with local and international researchers to drive forward the frontiers of oncology.

Locations

Cairo, , Egypt

Cairo, , Egypt

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported